Louisiana State Employees Retirement System increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,900 shares of the company’s stock after acquiring an additional 700 shares during the quarter. Johnson & Johnson comprises about 0.8% of Louisiana State Employees Retirement System’s investment portfolio, making the stock its 11th largest position. Louisiana State Employees Retirement System’s holdings in Johnson & Johnson were worth $29,836,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Veracity Capital LLC boosted its stake in shares of Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after acquiring an additional 59 shares during the period. Sandy Cove Advisors LLC lifted its holdings in Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after purchasing an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after purchasing an additional 62 shares during the last quarter. Mason & Associates Inc lifted its holdings in Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC lifted its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on JNJ. SVB Leerink decreased their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Finally, Atlantic Securities lifted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $173.67.
Johnson & Johnson Trading Down 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the company posted $2.13 EPS. The business’s revenue was down 4.4% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Hypercharge Networks: Up Triple Digits, But What’s The Big Deal?
- 3 Reasons Why Apple’s 30% Rally Has Legs
- 3 Reasons to Pick First Citizens Instead of First Republic Bank
- 3 April Earnings Plays for Bullish Swing Traders
- Is Constellation Brands Star About To Rise?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
